Explore our ACCC 2020 Impact Report, the Oncology Issues, Vol.36 N.5, and our video podcast, CANCER BUZZ TV.
ACORI: ACCC Community Oncology Research Institute



Home / Learn / Research & Clinical Trials / ACCC Community Oncology Research Institute

ACCC Community Oncology Research Institute

The Association of Community Cancer Centers (ACCC) has established the ACCC Community Oncology Research Institute (ACORI) to build on its existing mission to close the gap in cancer research through optimal oncology partnerships. ACORI will work to establish clinical trials as a standard of care in treatment plans and to help achieve equitable cancer care delivery for all patients.

The Institute evolved from ACCC’s year-long examination of equity and access to clinical trials in the community under the direction of its Immediate Past President Randall A. Oyer, MD, who will lead a Task Force of recognized multidisciplinary cancer team professionals.

 Randall Oyer

“Communities belong in cancer research and cancer research belongs in the community. Connecting community cancer centers through partnerships will help overcome persistent barriers that exist to conducting research in the community. By sharing resources, we can help make any community oncology program research-ready.”

Randall A. Oyer, MD
Medical Director, Oncology Program
Penn Medicine Lancaster General Health,
Lancaster, PA
ACCC 2020 - 2021 President

Three Primary Domains

EQUITY: We advocate for diversity, equity, and inclusion with trial sponsors and regulatory agencies. ACORI will develop education and resources that promote strategies and solutions to achieve health equity, as we investigate persistent areas of disparities in cancer clinical trial participation.

CAPACITY BUILDING: ACORI utilizes ACCC know-how to build capacity and competency among community research programs to make them research-ready by democratizing knowledge, skills, and infrastructure for clinical research. We will also facilitate mentorship opportunities between established and developing research programs and convene community oncology stakeholders for peer-to-peer learning and networking.

RESEARCH DIFFUSION: ACORI is a primary resource for academic and industry sponsors that fosters relationships with trial sponsors and other research groups. The Institute vets research and trial opportunities and disseminates pertinent opportunities to interested community oncology research programs.

Through ACCC’s robust network of partnerships, ACORI will enable community oncology programs and their multidisciplinary teams to access the tools, knowledge sharing, effective practices, and peer mentorships to increase their ability to offer trials to patients.

For more information about the ACCC Community Oncology Research Institute, please contact Janelle Schrag, MPH, Assistant Director, Research Programs, ACCC Provider Education.

Clinical Research Terms Glossary

This digital glossary of clinical research terms will help to establish a standardized understanding across cancer care team members and can serve as a tool to improve patient education and encourage shared decision-making conversations.

Access the Glossary

Featured Program

ASCO President Lori J. Pierce, MD, discusses the ASCO-ACCC Collaboration during her #ASCO21 President's Address.

ASCO-ACCC Initiative to Increase Racial and Ethnic Diversity in Clinical Trials

ACCC and ASCO are collaborating to increase cancer clinical trial participation among patients from underrepresented racial and ethnic groups. The two organizations are currently recruiting 40 oncology research programs to be part of a pilot program testing a site assessment tool and/or an implicit bias training program.
Learn More



Alex Spira[PODCAST] Mini-Podcast: Improving Community Clinical Trial Participation
October 13, 2020
Lack of community participation in cancer clinical trials has long been an issue, as has a lack of diversity among participants. On this CANCER BUZZ mini-podcast, learn about the importance of reaching diverse populations with clinical trials where they live and how one clinical trial has prioritized community engagement.

Alex Spira, MD, PhD, FACP, Medical Oncologist; Director, VCS Research Institute & Phase I Trial Program, Virginia Cancer Specialists


Our Supporters

abbvie-200x80 amgen-200x80 astrazeneca-200x80 bms-200x80 eisai-200x80 genentech-200x80 merck-200x80 sanofi-genzyme-200x80-long

This project is supported by AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Eisai, Genentech, Merck and Sanofi.